Evolve is a new kind of biologics company founded for a clear purpose: bringing critical plasma proteins to the people who need them.
Evolve is a new kind of biologics company. We’re built around a next-generation technology for bringing critical therapeutics to the people who need them.
People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For the past 80 years, these proteins have been captured through a largely unchanged yet expensive process. Until now.
We believe our patented next-generation technology, PlasmaCap EBA®, is the first major advancement in the field since the 1940s. We believe it will help us deliver critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods can.
Ultimately, Evolve aims to improve the lives of people within a largely underserved market—building a broad and innovative product portfolio in the process.
We believe we can deliver plasma-derived therapeutics at higher levels of purity, efficiency, and reliability than anyone in our industry currently delivers.
As a first step toward achieving that vision, we have advanced the technology used to extract plasma proteins from blood. We believe our patented technique, PlasmaCap EBA®, is the first major innovation in this area in the past 80 years.
We believe this technique will allow us to advance the quality of plasma-derived therapeutics. It has the potential to extract more value from each liter of precious donor plasma as compared to legacy technology.
And this efficiency drives reliability—in both quality and consistency of supply. Because our technology is proprietary and protected, and we have direct control of our manufacturing, we expect our supply to be more consistent and predictable than today’s options.
We think it’s about time someone advanced the way biologics are delivered. So Evolve is doing just that.